The vaccine Dengvaxia was developed by the French pharmaceutical company Sanofi Pasteur.
It may now be sold in some European overseas territories with a tropical climate, including La Reunion whose population has been badly hit by the mosquito-borne disease.
The use of Dengvaxia is restricted to people between the ages of 9 and 45 who have had dengue before.
The vaccine is to prevent a second dengue infection which researchers say tends to be more serious.
Dengvaxia has earlier been approved in countries like Brazil and Mexico while Sanofi expects a decision by the US by May.
SOURCE: RADIO NZ